Should estrone glucuronide (E1G) levels be higher on 8-10 days post ovulation (DPO) than on 7DPO in a pregnant patient undergoing fertility treatment with letrozole (letrozole) and progesterone supplementation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 22, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

E1G Levels During Early Pregnancy: Expected Pattern from 7-10 DPO

Estrone glucuronide (E1G) levels should rise progressively from 7 DPO through 8-10 DPO in a pregnant patient, reflecting continued follicular/corpus luteum activity and early placental hormone production.

Understanding E1G Patterns in Early Pregnancy

E1G serves as a direct marker of follicular growth and ovarian estrogen production, with rising levels indicating ongoing hormonal activity. 1, 2

  • In normal ovulatory cycles, E1G rises during the follicular phase, peaks around ovulation, and then shows variable patterns in the luteal phase depending on pregnancy status 1
  • A 50% rise in E1G concentration over the mean of three preceding values can be used to locate the start of the fertile period in >90% of ovarian cycles 1
  • E1G excretion rates provide direct, real-time monitoring of ovarian hormone activity without requiring population-based calculations 2

Expected E1G Trajectory in Early Pregnancy (7-10 DPO)

In a conception cycle, E1G levels typically continue to rise or remain elevated during the early luteal phase (7-10 DPO) as the corpus luteum maintains robust function to support early implantation. 2

  • The corpus luteum produces both progesterone and estrogen after ovulation, with estrogen production (measured as E1G) remaining active in pregnancy cycles 2
  • Early pregnancy requires sustained corpus luteum function, which produces both hormones until placental production takes over around 7-10 weeks gestation 2
  • E1G levels that decline precipitously after 7 DPO more commonly indicate a non-conception cycle 1, 2

Special Considerations with Letrozole Treatment

Letrozole use during ovulation induction may affect hormone patterns, though its primary impact is on estradiol levels during stimulation rather than post-ovulatory E1G patterns. 3

  • Letrozole maintains estradiol levels near physiologic ranges during ovarian stimulation, reducing OHSS risk 4, 5
  • While letrozole successfully lowers estradiol during the follicular phase in fertility preservation protocols, post-ovulatory hormone dynamics differ 3
  • Progesterone supplementation is strongly recommended in letrozole cycles for women with PCOS, as clinical pregnancy rates are significantly higher with luteal support (21.1% vs 0% in one study). 6

Progesterone vs E1G Monitoring

While E1G should rise, pregnanediol-3-glucuronide (PdG, the urinary progesterone metabolite) is actually a more reliable marker for confirming ovulation and luteal adequacy. 1, 2

  • Post-ovulatory PdG rise following an E1G peak provides good evidence of ovulation 2
  • Specific PdG values can determine whether a cycle is anovulatory, ovulatory-infertile, or ovulatory-fertile 2
  • Attempts to locate the end of the fertile period using PdG threshold values alone have been disappointing, requiring combined E1G/PdG ratio analysis 1

Clinical Pitfall to Avoid

Do not rely solely on E1G patterns to confirm early pregnancy, as progesterone (PdG) provides more definitive evidence of adequate luteal function. 1, 2

  • The E1G/PdG ratio provides better navigation of the fertility continuum than either hormone alone 1
  • In letrozole cycles specifically, ensure adequate progesterone supplementation is provided, as this significantly impacts pregnancy outcomes 6
  • Ultrasound monitoring remains essential during letrozole treatment cycles to confirm appropriate follicular development 4, 5

Related Questions

What seeds can help increase estrogen levels (E1G) during the luteal phase (7-10 days post-ovulation) in a female patient of reproductive age with a stage 3 rectocele undergoing fertility treatment with letrozole and progesterone supplementation?
What are the implications of an elevated estrone (E1G) level of 100 on cycle day 20, 7 days past the luteinizing hormone (LH) surge, in a patient undergoing fertility treatment with letrozole (Femara) (letrozole) from cycle day 3-7 and progesterone supplementation starting on the night of ovulation confirmation on cycle day 15, with a progesterone level (PDG) of 20?
Is an estrone (E1G) level of 100 and a progesterone (PDG) level of 20 at 7 days post-ovulation (7DPO) during fertility treatment with letrozole (Femara) and progesterone supplementation indicative of a hormonal imbalance?
Will tomorrow's E1G value at 8 dpo indicate pregnancy likelihood in a patient with a history of fluctuating E1G levels, stage 3 rectocele, and current fertility treatment with letrozole and progesterone?
What is the effect of letrozole (Femara) on luteal phase progesterone levels?
How do you manage iron levels in pediatric patients with acute myeloid leukemia (AML) who are at risk of iron overload due to frequent blood transfusions?
What is the dosage adjustment for ampicillin (Ampicillin)/sulbactam in a patient with impaired renal function?
What are the warning signs of preeclampsia in a pregnant patient with a history of diabetes and hypertension?
What is the recommended physiotherapy management for a patient with frozen shoulder?
What is the recommended post-resection care plan for a 50-year-old adult patient with a history of low-risk colon cancer?
Is Lunesta (eszopiclone) appropriate for a patient with a history of chronic respiratory failure with hypoxia and sarcoidosis of the lungs?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.